136 related articles for article (PubMed ID: 37179440)
1. Whole-exome and targeted gene sequencing of large-cell lung carcinoma reveals recurrent mutations in the PI3K pathway.
Guo JH; Ma YS; Lin JW; Jiang GX; He J; Lu HM; Wu W; Diao X; Fan QY; Wu CY; Liu JB; Fu D; Hou LK
Br J Cancer; 2023 Aug; 129(2):366-373. PubMed ID: 37179440
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
[TBL] [Abstract][Full Text] [Related]
3. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.
Li M; Zhang Z; Li X; Ye J; Wu X; Tan Z; Liu C; Shen B; Wang XA; Wu W; Zhou D; Zhang D; Wang T; Liu B; Qu K; Ding Q; Weng H; Ding Q; Mu J; Shu Y; Bao R; Cao Y; Chen P; Liu T; Jiang L; Hu Y; Dong P; Gu J; Lu W; Shi W; Lu J; Gong W; Tang Z; Zhang Y; Wang X; Chin YE; Weng X; Zhang H; Tang W; Zheng Y; He L; Wang H; Liu Y; Liu Y
Nat Genet; 2014 Aug; 46(8):872-6. PubMed ID: 24997986
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.
Pazarentzos E; Giannikopoulos P; Hrustanovic G; St John J; Olivas VR; Gubens MA; Balassanian R; Weissman J; Polkinghorn W; Bivona TG
Oncogene; 2016 Mar; 35(9):1198-205. PubMed ID: 25982275
[TBL] [Abstract][Full Text] [Related]
5. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
van der Wekken AJ; Kuiper JL; Saber A; Terpstra MM; Wei J; Hiltermann TJN; Thunnissen E; Heideman DAM; Timens W; Schuuring E; Kok K; Smit EF; van den Berg A; Groen HJM
PLoS One; 2017; 12(8):e0182885. PubMed ID: 28854272
[TBL] [Abstract][Full Text] [Related]
6. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
7. Correlation of genes associated with drug response to prognosis of large cell lung carcinoma.
Chen C; Jiang XL; Zhang CC; Li K
Chin J Cancer; 2011 Jul; 30(7):497-504. PubMed ID: 21718596
[TBL] [Abstract][Full Text] [Related]
8. SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy.
Ji X; Liu Y; Mei F; Li X; Zhang M; Yao B; Wu R; You J; Pei F
Sci Rep; 2021 Jul; 11(1):14031. PubMed ID: 34234236
[TBL] [Abstract][Full Text] [Related]
9. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
10. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
Lim SM; Kim HR; Cho EK; Min YJ; Ahn JS; Ahn MJ; Park K; Cho BC; Lee JH; Jeong HC; Kim EK; Kim JH
Oncotarget; 2016 Jun; 7(24):36311-36320. PubMed ID: 27121209
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
12. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
Mafficini A; Amato E; Cataldo I; Rusev BC; Bertoncello L; Corbo V; Simbolo M; Luchini C; Fassan M; Cantù C; Salvia R; Marchegiani G; Tortora G; Lawlor RT; Bassi C; Scarpa A
Ann Surg; 2018 Jan; 267(1):149-156. PubMed ID: 27611608
[TBL] [Abstract][Full Text] [Related]
13. Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing.
Su S; Zou JJ; Zeng YY; Cen WC; Zhou W; Liu Y; Su DH; Zhang XL; Huang HY; Lei A; Huang ZH; Jin Y; Li L; Su N; Xie YL; Zhao ZG; Liu JX
Biomed Res Int; 2019; 2019():6096350. PubMed ID: 31781628
[TBL] [Abstract][Full Text] [Related]
14. Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification.
Karlsson A; Brunnström H; Micke P; Veerla S; Mattsson J; La Fleur L; Botling J; Jönsson M; Reuterswärd C; Planck M; Staaf J
J Thorac Oncol; 2017 Aug; 12(8):1257-1267. PubMed ID: 28535939
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.
Carneiro JG; Couto PG; Bastos-Rodrigues L; Bicalho MA; Vidigal PV; Vilhena A; Amaral NF; Bale AE; Friedman E; De Marco L
Genet Res (Camb); 2014; 96():e002. PubMed ID: 24594201
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
17. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
[TBL] [Abstract][Full Text] [Related]
18. Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non-small-cell lung cancer.
Zheng S; Wang X; Fu Y; Li B; Xu J; Wang H; Huang Z; Xu H; Qiu Y; Shi Y; Li K
Bioengineered; 2021 Dec; 12(1):791-802. PubMed ID: 33629637
[TBL] [Abstract][Full Text] [Related]
19. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
[TBL] [Abstract][Full Text] [Related]
20. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
